Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures. The sensors detect a change in spacing of the material structures from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: A connecting element connects a first wall panel with a second wall panel. A first spring element is supported on the upper part of the connecting element and on one side of a first bend. A second spring element is supported on the upper part and on one side of a second bend. The other side of the second bend presses on one side of the first bend. The connecting element is introduced without a tool into a first slot of the first bend and the second bend is placed at a second slot over the connecting element.

Abstract: A support frame has at one or more lower cage corners a respective support, at which at least one damping element is arranged. The support has a U-shaped cross-section and can be inserted into a beam with C-shaped cross-section. The elevator cage is mounted on the damping elements, which can keep oscillations and vibrations away from the elevator cage. Near the inserted support, a device can be provided for raising the elevator cage if the support or at least one damping element has to be replaced.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures. The sensors detect a change in spacing of the material structures from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.

Abstract: A connecting element connects a first wall panel with a second wall panel. A first spring element is supported on the upper part of the connecting element and on one side of a first bend. A second spring element is supported on the upper part and on one side of a second bend. The other side of the second bend presses on one side of the first bend. The connecting element is introduced without a tool into a first slot of the first bend and the second bend is placed at a second slot over the connecting element.

Abstract: A support frame has at one or more lower cage corners a respective support, at which at least one damping element is arranged. The support has a U-shaped cross-section and can be inserted into a beam with C-shaped cross-section. The elevator cage is mounted on the damping elements, which can keep oscillations and vibrations away from the elevator cage. Near the inserted support, a device can be provided for raising the elevator cage if the support or at least one damping element has to be replaced.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.